- Category: Approved HCV Drugs
- Published on Thursday, 19 November 2015 00:00
- Written by Gilead Sciences
The U.S. Food and Drug Administration last week granted supplemental approval of Gilead Sciences' sofosbuvir/ledipasvir (Harvoni) single-tablet regimen for the treatment of hepatitis C virus genotypes 4, 5, and 6 and for HIV/HCV coinfected people. The FDA also said Harvoni plus ribavirin for 12 weeks is an alternative to a 24 weeks of Harvoni alone for treatment-experienced hepatitis C patients with liver cirrhosis.